D2R News

Stay informed about D2R updates by subscribing to our mailing list!

Funding Opportunities

Learn more about D2R's newly launched funding programs.

students walking outside


In Martha Crago's recent article, she writes about how the rapid development of mRNA vaccines against SARS-CoV-2 testified to what can be accomplished when the world’s scientists put their minds together, with industry and governments investing to accelerate progress.

person wearing white gloves prepares a needle

Funding Programs

D2R's Translational Impact Research funding program is now accepting Letters of Intent until 18 April 2024.

Tubes in centrifuge


Upcoming events include theTokyo Symposium on Genomic Medicine, Therapeutics and Health from April 8-13 2024 and a Symposium Honoring the legacy of Jerry Pelletier on May 3, 2024. 

D2R | DNA to RNA 

An inclusive Canadian approach to genomic-based RNA therapeutics 

The time is now for discovery and development of genome-guided, RNA-based precision medicines for Canada and for the world. With a landmark $165 million investment from the Canada First Research Excellence Fund, McGill’s world-leading research initiative DNA to RNA (D2R) will develop revolutionary genomic-based RNA medicines for all people of Canada.

Discover the initiative

D2R's vision for Canada

Create groundbreaking medical treatments
D2R will improve health through rapid deployment of new lower cost medical treatments for previously “undruggable” pharmaceutical targets and untreated medical conditions.
Tackle societal and policy issues
D2R will address unmet clinical needs of under-served groups, including Canada’s Indigenous and immigrant populations by engaging with patients, their families and patient organizations.
Accelerate “next-generation” drug development

D2R will catalyze Canadian pharma/biotech to create a major international hub for “next-generation” drug development, industry partnerships and startups.


Explore the research & impact

woman in lab coat looking through microscope

Our researchers & partners

McGill researchers have been uncovering the mechanisms and potential of RNA for over 50 years. From genomics and RNA biology to medicine and biomanufacturing, our research strengths cover the range of expertise needed to discover gene targets and develop new treatments for disease. 

Back to top